Printer Friendly

Abbott enrolls first US patient in study comparing XIENCE to coronary artery bypass surgery.

M2 PHARMA-October 4, 2011-Abbott enrolls first US patient in study comparing XIENCE to coronary artery bypass surgery(C)2011 M2 COMMUNICATIONS

4 October 2011 - US Abbott (NYSE:ABT) said on Tuesday it had started enrolling US patients in a global study dubbed EXCEL comparing XIENCE to coronary artery bypass surgery.

EXCEL is a prospective, multi-centre, randomised trial to evaluate the safety and efficacy of the XIENCE PRIME/XIENCE V Everolimus Eluting Coronary Stent Systems, compared to coronary artery bypass grafting (CABG), or surgery, in select patients with unprotected left main coronary artery disease.

Left main disease is a high-risk subset of coronary artery disease involving blockage of the left main coronary artery, which branches off the aorta to provide blood flow to the left ventricle of the heart.

Surgery traditionally has been the standard treatment for left main disease, with coronary stenting reserved only for patients at high risk for surgery who are "protected" by a previous bypass graft to at least one of the two major coronary arteries that branch off the left main artery, Abbott said.

The EXCEL study will assess "unprotected" patients with left main disease who have not received grafts to these arteries to determine whether coronary stenting can be an alternative to bypass surgery in these patients.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Oct 4, 2011
Words:223
Previous Article:FDA accepts for filing Yaupon's mechlorethamine gel NDA.
Next Article:Sobi's R&D head to step down.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters